Kian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.
Kian-Huat Lim, MD, PhD
Advertisement
Articles by Kian-Huat Lim, MD, PhD
Kian-Huat Lim, MD, PhD, discusses the current standard of care for patients with resectable or borderline resectable pancreatic cancer.
Kian-Huat Lim, MD, PhD, discusses factors influencing the choice between treatment with FOLFIRINOX or NALIRIFOX for metastatic pancreatic cancer.
Kian-Huat Lim, MD, PhD, discusses the current treatment options for patients with metastatic pancreatic cancer.
Advertisement
Latest Updated Articles
Dr Lim on Treatment With FOLFIRINOX vs NALIRIFOX in Metastatic Pancreatic CancerPublished: May 16th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
3
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5